Document is current
Any future updates will be listed below
-
Authors
Valic, Michael S.
Fisher, Carl J.
Zheng, Mark
Gregor, Alexander M.
Jiang, Wenlei
Chan, Conrad
Chan, Harley H. L.
El-Sayes, Abdullah
Zhang, Chris J.
Ye, Tina
Halim, Michael
Schimmer, Pamela
Li, Celina
Bernards, Nicholas
Chu, Arthur C. K.
Cai, Zhongli
Chen, Juan
Irish, Jonathan C.
Yasufuku, Kazuhiro
Weersink, Robert
Reilly, Raymond M.
Wilson, Brian C.
Zheng, Gang https://orcid.org/0000-0002-0705-7398
-
Funding
Funding for this research was provided by:
Terry Fox Research Institute (#1075, #1137)
Ontario Institute for Cancer Research (#P.CTP.698)
Princess Margaret Cancer Foundation
- License Information
-
More Information
Article History
Received: 15 May 2025
Accepted: 26 June 2025
First Online: 17 July 2025
Declarations
: All applicable international, national, and/or institutional guidelines for the care and use of laboratory animals in research were followed. Animal studies were conducted at the Animal Resource Centre at the University Health Network (Toronto, Canada) in accordance with protocols #6207 (rat) and #4959 (dog) approved by the Ontario Cancer Institute Animal Care Committee.
: MSV, BCW, and GZ declare equity ownership in Nanogenix Inc. (Chicago, IL, USA), a company responsible for the commercialisation of PORPHYSOMES. No representative of Nanogenix not listed among the authors edited, reviewed, or otherwise influenced the reporting of results in this manuscript. The remaining authors declare no potential conflicts of interest.
